Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion

Argenx CEO Tim Van Hauwermeiren Belgian biotech argenx’s autoimmune disease treatment Vyvgart (efgartigimod alfa) hit the Japan market last week. As a blockbuster hopeful with an analyst estimate of US$5-10 billion in global peak sales, the drug is expected to...read more